Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from Sarepta Therapeutics

Sarepta Therapeutics Sees RS Rating Rise To 75

A Relative Strength Rating upgrade for Sarepta Therapeutics shows improving technical performance. Will it continue?

Investors Business Daily

Arrowhead, Sarepta Skyrocket After Duo Inks A Whopping $11.38 Billion Deal

Shares of Arrowhead Pharmaceuticals catapulted Tuesday after the company inked a broad licensing deal with Sarepta Therapeutics.

Investors Business Daily

Analyst Expectations For Sarepta Therapeutics's Future

14 analysts have expressed a variety of opinions on Sarepta Therapeutics (NASDAQ:SRPT) over the past quarter, offering a diverse set of opinions from bullish to bearish.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Avidity Biosciences, Up 441%, Nears Another Record High As Dystrophy Space Heats Up

The three-horse race to treat a devastating form of muscular dystrophy is now down to two. And Avidity Biosciences is feeling bullish.

Investors Business Daily

How Avidity Biosciences Just Dropped The Hammer On Sarepta Therapeutics

Avidity unveiled promising results for its DMD treatment on Friday and the top-notch biotech stock catapulted. RNA stock is highly rated.

Investors Business Daily

Sarepta Therapeutics Scores 90-Plus RS Rating On Muscular Dystrophy Approval

Sarepta Therapeutics sees its Relative Strength Rating hit the elite 90-plus level.

Investors Business Daily

Sarepta Therapeutics Earns Membership In 95-Plus Composite Rating Club

The IBD SmartSelect Composite Rating for Sarepta Therapeutics increased from 92 to 99 Monday.

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

Why Sarepta's First-Quarter Report Is Already Dead In The Water: Analyst

Sarepta will likely miss first-quarter expectations, an analyst said Monday, noting Sarepta stock has taken a beating since its last report.

Investors Business Daily

Sarepta Crashes 37% After Its Gene Therapy Flops Its Biggest-Ever Test

Sarepta Therapeutics' gene therapy, Elevidys, faces an uphill regulatory journey, analysts said Tuesday on mixed test results.

Investors Business Daily

Sarepta Therapeutics Stock Showing Rising Relative Strength

Sarepta Therapeutics shows rising price performance, earning an upgrade to its IBD Relative Strength Rating

Investors Business Daily

Sarepta Therapeutics Dives On An Unexpected Holdup For Its Gene Therapy

The FDA pushed back its review of a highly anticipated gene therapy from Sarepta Therapeutics on Wednesday, prompting SRPT stock to tumble.

Investors Business Daily

Stocks Close Higher on Hopes for U.S. Debt Ceiling Resolution

What you need to know… The S&P 500 Index ($SPX ) (SPY ) Monday closed up +0.30%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up +0.14%, and the Nasdaq 100 Index ($IU ) (QQQ ) closed up +0.55%. Stock indexes Monday closed moderately higher on hopes that...

Barchart

FDA Group Backs Gene Therapy to Fight Degenerative Disease

A promising gene therapy got welcome news from regulators.

The Street

Sarepta Therapeutics Stock Skyrockets On FDA Surprise

A promising gene therapy got welcome news from regulators.

The Street

Get all your
news in one place.

100’s of premium titles.
One news app.

Barchart

Stocks Mixed as Hawkish Fed Comments Push Bond Yields Higher

What you need to know… The S&P 500 Index ($SPX ) (SPY ) today is up +0.03%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.05%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.05%. U.S. stocks this morning gave up an early advance...

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

the European Commission

689 stories

the Wall Street Journal

Bloomberg Intelligence

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.